Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program

INTRODUCTION: Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn’s disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J., Vermeire, Severine, Tyrrell, Helen, Hassanali, Azra, Lacey, Stuart, Tole, Swati, Tatro, Amanda R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467434/
https://www.ncbi.nlm.nih.gov/pubmed/32445184
http://dx.doi.org/10.1007/s12325-020-01366-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467434/
https://www.ncbi.nlm.nih.gov/pubmed/32445184
http://dx.doi.org/10.1007/s12325-020-01366-2

Ejemplares similares